3.1.1 Liraglutide: weight, ectopic fat, and reproductive endocrine outcomes In placebo-controlled trials with approximately 26 weeks of follow-up, liraglutide 1.8 mg/d demonstrated stable, clinically meaningful weight loss, accompanied by improvements in several reproductive endocrine markers
Flow Wellness understands that discarding unused medication can be frustrating, but patient safety is the priority
A full 61% are one-star reviews
Regarding hormonal treatment, due to the higher adenoma risk in glycogen storage disease type I, estrogens should be avoided
Weight loss can vary, depending on which GLP-1 drug you use and the dosage
Additionally, Tesofensine users reported feeling more energized and having more control over food cravings